The problem, as the authors note, is to manage the risks of loss against the chances of gain for both parties. This rather slim book is a blueprint for how small biotech firms can hookup with much larger partners to get capital and credibility. Inc. Collaborations between big drug companies and little biotechs have flourished.
Alliances now provide more than half the capital invested in biotechnology.
Big drug makers enter them to get in on the ground floor of products that can go into their pipelines, eventually perhaps to become blockbuster drugs for widespread illnesses. Little biotech firms go into alliances to get cash. Leading Biotechnology Alliances examines the business power relationships, the dynamics of interpersonal relationships within workgroups, and the values of the players. Right from the Start is a valuable checklist of what to do and what not to do for a scientist with a great concept who suddenly finds that the world of business demands straight answers and a path to turning a profit. For scientific highbrows who need the lowdown on how it's done, this book's the thing .